Abbvie Inc. · NYSE:ABBV
Abbvie — J.P. Morgan Healthcare Conference 2021
21 slides from Abbvie's conference presentation, Jan 12, 2021
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Richard Gonzalez Chairman and Chief Executive Officer January 12, 2021
Slide 2: Forward-Looking Statements and Non-GAAP Financial information
Forward-Looking Statements and Non-GAAP Financial information Some statements in this presentation are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expression
Slide 3: AbbVie is a Diversified Biopharmaceutical Company Well-Positioned for Sustainable Growth
AbbVie is a Diversified Biopharmaceutical Company Well-Positioned for Sustainable Growth Strong Leadership Positions in Attractive Growth Markets Immunology Hematologic Oncology Neuroscience Allergan Aesthetics Not for promotional use J.P. Morgan Healthcare Conference | January 12, 2021 3
Slide 4: Broad Portfolio and Pipeline of Attractive, Durable Growth Assets
Broad Portfolio and Pipeline of Attractive, Durable Growth Assets Large, Diverse On-Market Portfolio and Robust Pipeline of Novel Therapies Will Drive Return to Revenue Growth in 2024 ▪ Continued strong top-line growth expected leading up to U.S. Humira LOE event in 2023 ▪ Expect total company sales
Slide 5: A Unique Investment Opportunity Positioned for Continued Strong Shareholder Returns
A Unique Investment Opportunity Positioned for Continued Strong Shareholder Returns Compelling Capital Allocation Philosophy, Balanced Between Supporting Growth and Returning Capital to Shareholders ▪ Strong operating cash flow to support investments for growth, return of cash to shareholders and ra
Slide 6: Track Record of Strong Financial Execution and Delivering Outstanding Shareholder Value
Track Record of Strong Financial Execution and Delivering Outstanding Shareholder Value / Return of Cash Consistently Delivered Adjusted Net Revenue Top-Tier Performance +13.5% CAGR 2013-2020* Met or Exceeded Key Adjusted EPS Financial Goals Since Becoming +18.8% CAGR 2013-2020* Independent Company
Slide 7: AbbVie Immunology
AbbVie Immunology Best-in-Class Medicines and Innovative Pipeline Position AbbVie for Sustained Leadership in Immunology RHEUMATOLOGY DERMATOLOGY GASTROENTEROLOGY AS / RA PsA PsO AD HS CD UC NR-axSpA Ph2 Ph3 Ph3 Ph3 Ph2 Ph3 Ph3 Currently Approved Under Regulatory Review Early-Stage Immunology Progra
Slide 8: Rinvoq and Skyrizi Represent Tremendous Long-Term Value
Rinvoq and Skyrizi Represent Tremendous Long-Term Value >$15.0B ▪ Adding new indications in 2021-2025 timeframe and Expected Combined ramping to peak share 2025-2030, both Rinvoq and Risk-Adjusted Global Sales Skyrizi expected to peak in early 2030s $1B ▪ Based on the launch trajectory in their init
Slide 9: AbbVie Hematologic Oncology
AbbVie Hematologic Oncology $6.6 Billion Franchise with Continued Strong Growth Over Next Decade ▪ First-in-class BTK inhibitor has transformed treatment ▪ First-in-class Bcl-2 inhibitor with 5 FDA Breakthrough paradigm; Gold standard in CLL and the preferred Therapy designations and 4 approved indi
Slide 10: AbbVie Oncology R&D
AbbVie Oncology R&D Building a Broader, Deeper Pipeline to Address Significant Unmet Need in Oncology Apoptosis & Tumor Novel Regulated Cell Death Targeting Immuno-Oncology First and best-in-class assets in Superior bispecifics and conjugates Novel assets that restore T-cell apoptosis that will expa
Slide 11: AbbVie Neuroscience
AbbVie Neuroscience $5 Billion Portfolio with Opportunity for Significant Growth Migraine Psychiatry Market leading migraine portfolio with options for Aspire for industry leadership in mood, anxiety and every patient across the migraine spectrum thought disorders with high unmet need • Botox Therap
Slide 12: Migraine Portfolio
Migraine Portfolio Building a Leading Portfolio with Options for Every Patient Across the Migraine Spectrum U.S. Migraine Market 1-3 Migraine Days / Month 4-7 Migraine Days 8-14 Migraine Days 15+ Days 14.1M patients 8.5M patients 5.6M patients 3.3M patients Prevention Therapies Atogepant Acute Treat
Slide 13: Vraylar
Vraylar A Versatile Atypical Antipsychotic With Compelling Benefit:Risk Profile Vraylar provides strong efficacy across multiple symptoms, with minimal impact on weight, lipids and fasting blood glucose Atypical antipsychotics that treat multiple symptoms receive a greater share of the atypical mark
Slide 14: Aesthetics Portfolio
Aesthetics Portfolio Expect to Grow High-Single Digits Annually Over Next Decade Leadership Positions in the U.S. Across All Areas Body Regenerative Toxins Fillers Plastics Contouring Medicine #1 #1 #1 #1 #1 66% 46% 67% 54% 51% Market Share Market Share Market Share Market Share Market Share New Pro
Slide 15: Developing Innovative Procedures to Drive Advancement of Aesthetics Medicine
Developing Innovative Procedures to Drive Advancement of Aesthetics Medicine Advance and Accelerate Drive Next-Generation Lead Industry in Pipeline Technologies Digital Technologies ▪ Indication Expansion: 10 active ▪ Toxins: Developing a portfolio of novel ▪ Developing innovative digital programs a
Slide 16: AbbVie R&D Pipeline
As of January 12, 2021 AbbVie R&D Pipeline Phase 1 Phase 2 Registrational / Phase 3 Submitted ■ ABBV-157 (RORgT) PsO ■ ABBV-154 (TNF-Steroid ADC) RA ■ Rinvoq (JAK 1) CD ■ Rinvoq (JAK 1) PsA ■ ABBV-022 (IL-22) UC ■ Rinvoq (JAK 1) HS ■ Rinvoq (JAK 1) UC ■ Rinvoq (JAK 1) AD ■ ABBV-151 (GARP+TGFb1) Soli
Slide 17: Anticipated Key Pipeline Events
Anticipated Key Pipeline Events 2021 2022 Regulatory Rinvoq – Atopic Dermatitis Skyrizi – CD Imbruvica + Venclexta – 1L CLL Rinvoq – Psoriatic Arthritis Skyrizi – PsA Imbruvica + Venclexta – R/R MCL Approvals Rinvoq – Ankylosing Spondylitis Rinvoq – UC Imbruvica – 1L MCL Atogepant – Episodic migrain
Slide 18: AbbVie: A Unique Investment Opportunity Poised for Continued Strong Shareholder Returns
AbbVie: A Unique Investment Opportunity Poised for Continued Strong Shareholder Returns Portfolio of leading brands in attractive and sustainable markets Pipeline of innovative, highly differentiated assets to address significant unmet needs, with potential to drive significant growth Compelling cap
Slide 19: Qobvie
Qobvie
Slide 20: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Diluted earnings per share 2013 2014 2015 2016 2017 2018 2019 2020E As reported (GAAP) $2.56 $1.10 $3.13 $3.63 $3.30 $3.66 $5.28 $3.90 Adjusted for specified items: Acquisition related costs 0.23 0.18 0.45 0.68 0.93 1.00 3.23 5.87 Separation costs 0.10 0.24 0.13 -- -
Slide 21: AbbVie's Partnered Assets
AbbVie’s Partnered Assets • Skyrizi developed in cooperation with Boehringer Ingelheim • Imbruvica jointly developed and commercialized with Janssen Biotech • Venclexta developed by AbbVie and Roche, commercialized by AbbVie and Genentech, a member of the Roche Group • Epcoritamab, GEN1044 and GEN30